In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
[11C]Flumazenil shows promise as a clinical and research PET radiotracer to image changes in GABAA central benzodiazepine receptor (cBZR), but its widespread use has been limited by practical limitations of [11C]. This study evaluated the imaging characteristics of two fluorinated PET radiotracers in rats in vivo: [18F]fluoroflumazenil ([18F]FFMZ) and [18F]flumazenil ([18F]FMZ).
PET acquisitions were performed on a small-animal scanner following injection of [18F]FFMZ in nine rats and [18F]FMZ in eight rats. The following treatments were investigated: (1) injection of the tracer dose, (2) presaturation then injection of the tracer dose, and (3) injection of the tracer dose followed by a displacement injection. Unchanged tracer was measured in plasma and brain structures in four animals 10 and 30 min after injection, and ex-vivo autoradiography was also performed.
For both [18F]FFMZ and [18F]FMZ maximal brain activity peaked rapidly, and was highest in the hippocampus (1.12±0.06 SUV, 1.24±0.10 SUV, respectively), and lowest in the pons (1.00±0.07 SUV, 1.03±0.09 SUV, respectively). By 50 min after injection, maximal uptake for [18F]FFMZ and [18F]FMZ had decreased in the hippocampus to 18±3% and 80±1% (p<0.01), respectively. The presaturation and displacement studies showed a higher nonspecific component for [18F]FFMZ than for [18F]FMZ. Metabolite studies showed that at 30 min only 10% of the signal was from [18F]FFMZ in the brain. This nonspecific binding was apparent on autoradiography. In contrast, [18F]FMZ accounted for >70% of the signal in the brain, which resulted in well-defined regional binding on autoradiography.
These results demonstrate that [18F]FMZ is a superior radiotracer to [18F]FFMZ for in-vivo PET imaging of the GABAA/cBZR, having slower metabolism and leading to lower concentrations of metabolites in the brain that results in a substantially better signal-to-noise ratio.
- Haefely W. Antagonists of benzodiazepines: functional aspects. Adv Biochem Psychopharmacol 1983;38:73–93.
- Leveque P, Labar D, Gallez B. Biodistribution, binding specificity and metabolism of [18F]fluoroethylflumazenil in rodents. Nucl Med Biol 2001;28(7):809–14. CrossRef
- Grunder G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz HG, Stoeter P, et al. [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur J Nucl Med 2001;28(10):1463–70. CrossRef
- Mitterhauser M, Wadsak W, Wabnegger L, Mien L-K, Togel S, Langer O, et al. Biological evaluation of 2′-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nucl Med Biol 2004;31(2):291–5. CrossRef
- Chang YS, Jeong JM, Yoon YH, Kang WJ, Lee SJ, Lee DS, et al. Biological properties of 2′-[18F]fluoroflumazenil for central benzodiazepine receptor imaging. Nucl Med Biol 2005;32(3):263–8. CrossRef
- Ryzhikov NN, Seneca N, Krasikova RN, Gomzina NA, Shchukin E, Fedorova OS, et al. Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol 2005;32(2):109–16. CrossRef
- Yoon YH, Jeong JM, Kim HW, Hong SH, Lee YS, Kil HS, et al. Novel one-pot one-step synthesis of 2′-[(18)F]fluoroflumazenil (FFMZ) for benzodiazepine receptor imaging. Nucl Med Biol 2003;30(5):521–7. CrossRef
- Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging 2007;34(4):532–40. CrossRef
- Mandema JW, Gubbens-Stibbe JM, Danhof M. Stability and pharmacokinetics of flumazenil in the rat. Psychopharmacology (Berl) 1991;103(3):384–7. CrossRef
- Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 2000;27(6):627–30. CrossRef
- Halldin C, Stone-Elander S, Thorell J-O, Persson A, Sedvall G. 11C-Labelling of Ro 15-1788 in two different positions, and also 11C-labelling of its main metabolite Ro 15-3890, for PET studies of benzodiazepine receptors. Appl Radiat Isot 1988;39(9):993–7. CrossRef
- Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS, et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med 2006;47(3):520–7.
- Tewson TJ, Welch MJ. Preparation and preliminary biodistribution of “no carrier added” fluorine-18 fluoroethanol. J Nucl Med 1980;21(6):559–64.
- Kleingeist B, Bocker R, Geisslinger G, Brugger R. Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase. J Pharm Pharm Sci 1998;1(1):38–46.
- In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat
European Journal of Nuclear Medicine and Molecular Imaging
Volume 36, Issue 6 , pp 958-965
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- GABAA/cBZ receptor
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine (RMH), University of Melbourne, Royal Parade, Parkville, 3050, VIC, Australia
- 2. Radiopharmaceuticals Research Institute, ANSTO, Sydney, Australia
- 3. Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia